Pharmaceutical manufacturers face unprecedented operational pressures as demand for GLP-1 receptor agonists outstrips global sterile manufacturing capacity.
Fill-Finish Production Constraints
The primary limiting factor remains specialized sterile fill-finish operations for auto-injector devices. Drugmakers are acquiring third-party contract development and manufacturing organizations (CDMOs) to address deficits.
Cold-Chain Infrastructure Expansion
Logistics providers are expanding temperature-controlled warehousing to maintain 2°C to 8°C storage compliance throughout global shipping networks.